Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hidehiro Ishikawa

Showing results (51-60 of 53) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 53 results.
Biorxiv : the Preprint Server for Biology|February 24, 2023
Aerobic exercise reverses aging-induced depth-dependent decline in cerebral microcirculationPaul Shin, Qi Pian, Hidehiro Ishikawa, et al.
Elife|July 4, 2023
Aerobic exercise reverses aging-induced depth-dependent decline in cerebral microcirculationPaul Shin, Qi Pian, Hidehiro Ishikawa, et al.
BMJ Open|July 1, 2021
Repurposing bromocriptine for Aβ metabolism in Alzheimer's disease (REBRAnD) study: randomised placebo-controlled double-blind comparative trial and open-label extension trial to investigate the safety and efficacy of bromocriptine in Alzheimer's disease with presenilin 1 (PSEN1) mutationsTakayuki Kondo, Haruhiko Banno, Taro Okunomiya, et al.
Pageof 6

Showing results (51-60 of 53) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 53 results.
Biorxiv : the Preprint Server for Biology|February 24, 2023
Aerobic exercise reverses aging-induced depth-dependent decline in cerebral microcirculationPaul Shin, Qi Pian, Hidehiro Ishikawa, et al.
Elife|July 4, 2023
Aerobic exercise reverses aging-induced depth-dependent decline in cerebral microcirculationPaul Shin, Qi Pian, Hidehiro Ishikawa, et al.
BMJ Open|July 1, 2021
Repurposing bromocriptine for Aβ metabolism in Alzheimer's disease (REBRAnD) study: randomised placebo-controlled double-blind comparative trial and open-label extension trial to investigate the safety and efficacy of bromocriptine in Alzheimer's disease with presenilin 1 (PSEN1) mutationsTakayuki Kondo, Haruhiko Banno, Taro Okunomiya, et al.
Pageof 6